THIS YEAR, the European Academy of Dermatology and Venereology (EADV) adopted a pioneering hybrid format for its congress, allowing delegates to attend onsite in Milan, Italy, as well as online. Clinicians and academics came together with one common goal: to build an international community that develops, shares, and adopts best practices within the fields of dermatology and venereology.

Lichen sclerosus et atrophicus (LSEA) is an inflammatory skin disease that most frequently affects pre-pubertal and post-menopausal females. It commonly affects anogenital skin; however, extragenital lesions are not uncommon and occur in isolation or concomitantly with genital lesions.

The European Academy of Dermatology and Venereology’s (EADV) 31st Congress took place between 7th and 10th September 2022. This hybrid congress offered both a long-awaited onsite experience and the opportunity to attend virtually from across the globe.

Chronic spontaneous urticaria (CSU) is characterised by the spontaneous occurrence of wheals (hives) and/or angioedema for ≥6 weeks.1 CSU can persist for several years and is associated with severe pruritus. Skin mast cell activation in CSU occurs via Type I autoallergy driven by IgE to autoallergens, and a Type IIb autoimmune response due to mast cell-targeted autoantibodies against IgE or high-affinity IgE receptor.

The following highlights spotlight abstracts presented at the European Academy of Dermatology and Venereology (EADV) Congress 2022, specifically focusing on the latest developments in nail disorders and urticaria.

DURING the 31st Annual European Academy of Dermatology and Venereology (EADV) Congress, 7th–10th September 2022, held both in-person in Milan, Italy, and virtually, experts delivered a session on the topic of nail disorders.

The primary endpoint analyses from the SUNSHINE and SUNRISE Phase III trials of secukinumab in moderate-to-severe hidradenitis suppurativa (HS) were featured in an oral presentation as part of the late-breaking news session at the 31st annual European Academy of Dermatology and Venereology (EADV) congress. Known collectively as the SUNNY trials, the SUNSHINE and SUNRISE studies represent the largest Phase III trials conducted in HS to date.

EMJ spoke to Christa De Cuyper about her roles within the European Academy of Dermatology and Venereology (EADV), including the recent Nurses in Dermatology Practice event, which De Cuyper co-chaired.